Antares Pharma Inc (ATRS) Stock
ATRS is no longer traded. Antares Pharma was delisted from the Nasdaq in May 2022.
Prices on this page are historical; the last trade was May 20, 2022 at $5.59.
Antares Pharma stock price history
ATRS final trading statistics
- Final close
- $5.59
- Final trading day
- May 20, 2022
- Market cap at delisting
- $955.06M
- Shares outstanding
- 170.85M
- Final 52-week range
- $3.11 – $5.59
- Avg. volume (final 3 mo.)
- 4,867,374
- All-time high (split-adj.)
- $29.38 · Jan 1997
- All-time low (split-adj.)
- $0.32 · Dec 2008
- Return since IPO
- -78.7%
- Beta
- 1.15
- Book value / share
- $1.03
- Price / book
- 5.43
Antares Pharma annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $183.98M | $46.3M | $0.27 |
| FY2020 | $149.60M | $56.2M | $0.06 |
| FY2019 | $123.86M | -$2.0M | $0.00 |
| FY2018 | $63.55M | -$6.5M | -$0.12 |
| FY2017 | $54.52M | -$16.7M | -$0.10 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Antares Pharma Inc
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a
Antares Pharma stock FAQ
What happened to Antares Pharma stock?
Antares Pharma stock was delisted from the Nasdaq. Its final close was $5.59 on May 20, 2022.
Is ATRS stock still trading?
No. ATRS was delisted from the Nasdaq in May 2022 and no longer trades on a U.S. exchange.
What was the last price of ATRS stock?
ATRS closed at $5.59 on its final trading day, May 20, 2022, for a market value of about $955.06M.
What were Antares Pharma's revenue and earnings in its last full fiscal year?
Antares Pharma reported revenue of $183.98M and net income of $46.3M in fiscal 2021, its last full year as a public company.
When did Antares Pharma go public?
Antares Pharma Inc stock began trading on October 2, 1996.